134 related articles for article (PubMed ID: 2291265)
21. [Methods in nuclear medicine and their significance for diagnosis of gastrointestinal diseases].
van de Flierdt E; Avril N; Martin WG; Langhammer HR; Pabst HW
Internist (Berl); 1993 Mar; 34(3):253-60. PubMed ID: 8473100
[No Abstract] [Full Text] [Related]
22. Significance of myofibroblast appearance in squamous cell carcinoma of the oral cavity on the occurrence of occult regional metastases, distant metastases, and survival.
Luksic I; Suton P; Manojlovic S; Virag M; Petrovecki M; Macan D
Int J Oral Maxillofac Surg; 2015 Sep; 44(9):1075-80. PubMed ID: 26055525
[TBL] [Abstract][Full Text] [Related]
23. [Tumor markers in gynecology].
Fuith LC; Artner-Dworzak E; Daxenbichler G
Wien Klin Wochenschr; 1989 Jul; 101(14):489-91. PubMed ID: 2672608
[TBL] [Abstract][Full Text] [Related]
24. [The significance of screening studies for the early detection of metastases in curatively operated breast carcinoma].
Fenner D; Hofmann V
Schweiz Med Wochenschr; 1988 Feb; 119(5):156-9. PubMed ID: 3238401
[TBL] [Abstract][Full Text] [Related]
25. Clinical utility of diagnostic markers for malignant pleural mesothelioma.
Grigoriu BD; Grigoriu C; Chahine B; Gey T; Scherpereel A
Monaldi Arch Chest Dis; 2009 Mar; 71(1):31-8. PubMed ID: 19522163
[TBL] [Abstract][Full Text] [Related]
26. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
[TBL] [Abstract][Full Text] [Related]
27. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
28. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
Duffy MJ; van Rossum LG; van Turenhout ST; Malminiemi O; Sturgeon C; Lamerz R; Nicolini A; Haglund C; Holubec L; Fraser CG; Halloran SP
Int J Cancer; 2011 Jan; 128(1):3-11. PubMed ID: 20824704
[TBL] [Abstract][Full Text] [Related]
29. [What are tumor markers, and what is their value?].
von Kleist S
Wien Klin Wochenschr; 1989 Jul; 101(14):459-63. PubMed ID: 2672605
[TBL] [Abstract][Full Text] [Related]
30. [Basic principles and medical responsibilities in tumor after-care].
Ebeling K; Bodek B
Z Arztl Fortbild (Jena); 1981 Jun; 75(11-12):534-40. PubMed ID: 6171108
[No Abstract] [Full Text] [Related]
31. [Tumor markers of breast cancer].
Sławicki S; Mroczko B; Szmitkowski M
Postepy Hig Med Dosw (Online); 2004 Jul; 58():292-300. PubMed ID: 15280799
[TBL] [Abstract][Full Text] [Related]
32. Selective recognition of a saccharide-type tumor marker with natural and synthetic ligands: a new trend in cancer diagnosis.
Kejík Z; Bříza T; Králová J; Martásek P; Král V
Anal Bioanal Chem; 2010 Nov; 398(5):1865-70. PubMed ID: 20820999
[TBL] [Abstract][Full Text] [Related]
33. [Differential after care for early detection of recurrence--from the general practice viewpoint].
Rehner M
Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990; ():247-9. PubMed ID: 1983558
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
35. [Tumor markers--how they should be applied].
Stieber P; Heinemann V; Schalhorn A
MMW Fortschr Med; 2005 May; 147(20):35, 37-9. PubMed ID: 15957858
[TBL] [Abstract][Full Text] [Related]
36. [Treatment monitoring, recurrence detection, prognosis. Here's where tumor markers make good sense].
Lamerz R; Stieber P
MMW Fortschr Med; 2002 Oct; 144(41):26-8, 30-2. PubMed ID: 12474357
[TBL] [Abstract][Full Text] [Related]
37. [Tumor markers useful in the diagnostics and monitoring of endometrial and cervical cancer].
Bedkowska GE; Lawicki S; Szmitkowski M
Postepy Hig Med Dosw (Online); 2007; 61():122-8. PubMed ID: 17369780
[TBL] [Abstract][Full Text] [Related]
38. [Tumor markers in the upper intestinal tract--stomach and pancreas].
Pointner R; Conrad F; Schwab G
Wien Klin Wochenschr; 1989 Jul; 101(14):482-4. PubMed ID: 2773485
[TBL] [Abstract][Full Text] [Related]
39. Dynamic use of tumor markers, rationale-clinical applications and pitfalls.
Gion M; Mione R; Barioli P; Dittadi R
Anticancer Res; 1996; 16(4B):2279-84. PubMed ID: 8694556
[TBL] [Abstract][Full Text] [Related]
40. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?
van der Harst E; Bruining HA; Jaap Bonjer H; van der Ham F; Dinjens WN; Lamberts SW; de Herder WW; Koper JW; Stijnen T; Proye C; Lecomte-Houcke M; Bosman FT; de Krijger RR
J Pathol; 2000 Jun; 191(2):175-80. PubMed ID: 10861578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
